Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Tovecimig · 1 trial · 2 indications
Defined as the proportion of patients who have a partial response (PR) or complete response (CR) per RECIST 1.1. CR is defined as disappearance of all target lesions and disappearance of all non-target lesions and normalization of tumor marker level. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. PR is defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters.
| Arm | Type | Description |
|---|---|---|
| Tovecimig and Irinotecan + Leucovorin + 5-Fluorouracil (FOLFIRI regimen) | EXPERIMENTAL | Treatment will be administered in 28-day cycles. On Day 1 and 15 of each cycle, patients will receive Tovecimig followed by the FOLFIRI regimen. |
| Name | Type | Description |
|---|---|---|
| Tovecimig | BIOLOGICAL | Tovecimig is provided in 10 mg/kg dose intravenously over the course of 60 minutes on Day 1 and Day 15 of a 28-day cycle. |
| Irinotecan | DRUG | Standard of care irinotecan will be given at a dose of 180 mg/m\^2 intravenously on Day 1 and Day 15 of each 28-day cycle as part of the FOLFIRI treatment regimen. |
| Leucovorin | DRUG | Standard of care leucovorin will be given at a dose of 400 mg/m\^2 intravenously on Day 1 and Day 15 of each 28-day cycle as part of the FOLFIRI treatment regimen. |
| 5-Fluorouracil (5-FU) | DRUG | Standard of care 5-FU will be given at a dose of 2400 mg/m\^2 in continuous infusion over 46 hours on Days 1-2 and Days 15-16 of each 28-day cycle as part of the FOLFIRI treatment regimen. |
Inclusion Criteria: * Histologically or cytologically confirmed CRC. * Patient must have undergone resection of his/her primary tumor either as part of treatment for early stage disease with subsequent metastatic progression or due to a tumor related complication in the metastatic setting (e.g. bow...
Top 20 of 77 competitors
Tovecimig is an investigational monoclonal antibody being developed for the treatment of colorectal cancer, specifically metastatic colorectal cancer. It is currently being studied in a Phase 2 clinical trial as a second-line treatment in combination with FOLFIRI chemotherapy.
Tovecimig is a monoclonal antibody, but its specific molecular target has not been disclosed. The drug is being studied in a biomarker-selected patient population, suggesting it may target a specific molecular pathway relevant to colorectal cancer, though the exact target is not publicly detailed.
Tovecimig is being developed by COMPASS Pathways Plc, a biopharmaceutical company listed on the stock exchange under the ticker symbol CMPS. The company is conducting clinical research on this drug for oncology indications.
Tovecimig is currently in Phase 2 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities and is still undergoing clinical trials to evaluate its safety and efficacy in patients with metastatic colorectal cancer.
Tovecimig is being evaluated in a Phase 2 clinical trial with the identifier NCT07662031, titled 'Tovecimig Plus FOLFIRI in Second Line Metastatic Colorectal Cancer.' This trial is not yet recruiting and aims to enroll 25 patients in the United States.
Tovecimig is a distinct investigational drug and no alternative names have been reported. It is a monoclonal antibody being studied specifically for colorectal cancer, and it is not known to be identical to any other approved or investigational therapy.